NLRP3 and Alzheimer disease: Taken together, NLRP3 inhibitors clearly show efficacy in attenuating microglial activation and reactive astrogliosis, representing inflammasome inhibitors as potential drug class for the treatment of cerebrovascular related dementia including AD, PSD, and VCID.